Physician profile
Tracy Perkins
NPI 1346269347
$631.31
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.43 · 2022: $398 · 2023: $65.67 · 2024: $99.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $164.32 | 2022 | |
| Augmedics INC. | $117.53 | 2022-2024 | Xvision |
| Abbvie INC. | $73.10 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.69 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $28.50 | 2022 | |
| Lilly USA, LLC | $26.98 | 2022 | |
| Lundbeck LLC | $26.71 | 2022 | |
| Pfizer INC. | $25.27 | 2023 | |
| Amgen INC. | $24.48 | 2022 | |
| Aesculap Implant Systems, LLC | $24.01 | 2022 | |
| Ibsa Pharma INC. | $22.78 | 2023 | Tirosint, Licart |
| Arteriocyte Medical Systems, INC. | $22.70 | 2021 | |
| Nevro Corp. | $17.61 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.04 | 2021 | |
| Hikma Pharmaceuticals USA | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.